L.J.C. van Warmerdam

1.1k total citations
33 papers, 830 citations indexed

About

L.J.C. van Warmerdam is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, L.J.C. van Warmerdam has authored 33 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 10 papers in Cancer Research. Recurrent topics in L.J.C. van Warmerdam's work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (9 papers) and Neutropenia and Cancer Infections (8 papers). L.J.C. van Warmerdam is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (9 papers) and Neutropenia and Cancer Infections (8 papers). L.J.C. van Warmerdam collaborates with scholars based in Netherlands, United States and Germany. L.J.C. van Warmerdam's co-authors include Jos H. Beijnen, R. A. A. Maes, W.W. ten Bokkel Huinink, Sjoerd Rodenhuis, Hilde Rosing, Jan H.M. Schellens, Olaf van Tellingen, R. A. A. Maes, Brian E. Davies and Jaap Verweij and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

L.J.C. van Warmerdam

33 papers receiving 803 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L.J.C. van Warmerdam Netherlands 16 486 226 216 156 120 33 830
Robert J. Cersosimo United States 16 744 1.5× 319 1.4× 187 0.9× 189 1.2× 283 2.4× 43 1.4k
Jill Kolesar United States 19 329 0.7× 296 1.3× 102 0.5× 146 0.9× 139 1.2× 68 948
Von Hoff United States 16 540 1.1× 295 1.3× 170 0.8× 100 0.6× 171 1.4× 39 1.1k
Roberta Maltoni Italy 21 722 1.5× 338 1.5× 99 0.5× 376 2.4× 299 2.5× 84 1.2k
F Larra France 13 508 1.0× 205 0.9× 161 0.7× 74 0.5× 166 1.4× 39 917
Virginia E. Kwitkowski United States 16 423 0.9× 484 2.1× 192 0.9× 176 1.1× 264 2.2× 18 1.2k
Justin D. Floyd United States 11 475 1.0× 121 0.5× 121 0.6× 72 0.5× 178 1.5× 17 846
Els O. Witteveen Netherlands 14 536 1.1× 434 1.9× 46 0.2× 178 1.1× 158 1.3× 23 1.1k
Pilar Zamora Spain 17 303 0.6× 270 1.2× 110 0.5× 202 1.3× 195 1.6× 55 795
Călin Cainap Romania 18 376 0.8× 404 1.8× 339 1.6× 356 2.3× 257 2.1× 63 1.5k

Countries citing papers authored by L.J.C. van Warmerdam

Since Specialization
Citations

This map shows the geographic impact of L.J.C. van Warmerdam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L.J.C. van Warmerdam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L.J.C. van Warmerdam more than expected).

Fields of papers citing papers by L.J.C. van Warmerdam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L.J.C. van Warmerdam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L.J.C. van Warmerdam. The network helps show where L.J.C. van Warmerdam may publish in the future.

Co-authorship network of co-authors of L.J.C. van Warmerdam

This figure shows the co-authorship network connecting the top 25 collaborators of L.J.C. van Warmerdam. A scholar is included among the top collaborators of L.J.C. van Warmerdam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L.J.C. van Warmerdam. L.J.C. van Warmerdam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schipper, Robert‐Jan, et al.. (2024). Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy – A two center cohort study. European Journal of Surgical Oncology. 50(9). 108472–108472. 4 indexed citations
2.
Voort, Anna van der, Mette S. van Ramshorst, Erik van Werkhoven, et al.. (2020). Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial.. Journal of Clinical Oncology. 38(15_suppl). 501–501. 24 indexed citations
3.
4.
Vugts, Guusje, Adriana J. G. Maaskant-Braat, Adri C. Voogd, et al.. (2018). Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status. The Breast Journal. 24(6). 894–901. 5 indexed citations
5.
Bos, Monique E.M.M., Marta López‐Yurda, Jeany M. Rademaker-Lakhai, et al.. (2018). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Research and Treatment. 172(2). 413–423. 12 indexed citations
6.
Vriens, Birgit E. P. J., Ingeborg J. H. Vriens, Maureen J.B. Aarts, et al.. (2017). Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Research and Treatment. 165(3). 593–600. 10 indexed citations
7.
Charehbili, Ayoub, Saskia van de Ven, Vincent T.H.B.M. Smit, et al.. (2014). Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Annals of Oncology. 25(5). 998–1004. 31 indexed citations
8.
Hellemond, Irene E.G. van, G.J. Creemers, L.J.C. van Warmerdam, Floris A. de Jong, & Rutger H.T. Koornstra. (2013). Panitumumab Monotherapy as a Second-line Treatment in Metastasised Colorectal Cancer: A Single Centre Experience. Clinical Oncology. 26(3). 135–141. 2 indexed citations
9.
Slingerland, Marije, Henk‐Jan Guchelaar, Hilde Rosing, et al.. (2013). Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) Formulation and Paclitaxel in Polyethoxylated Castor Oil: A Randomized, Two-Period Crossover Study in Patients With Advanced Cancer. Clinical Therapeutics. 35(12). 1946–1954. 69 indexed citations
10.
Vriens, Birgit E. P. J., Maureen J.B. Aarts, Bart de Vries, et al.. (2013). Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. European Journal of Cancer. 49(15). 3102–3110. 31 indexed citations
11.
Vries, Jolanda De, et al.. (2012). Chemotherapy and cognitive complaints in women with breast cancer. Psycho-Oncology. 22(8). 1783–1789. 36 indexed citations
12.
Panday, Vinodh R. Nannan, L.J.C. van Warmerdam, Manon Huizing, et al.. (1999). A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen. Cancer Chemotherapy and Pharmacology. 43(5). 435–438. 11 indexed citations
13.
Panday, Vinodh R. Nannan, L.J.C. van Warmerdam, Manon Huizing, et al.. (1999). A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel. Journal of Cancer Research and Clinical Oncology. 125(11). 615–620. 11 indexed citations
14.
Warmerdam, L.J.C. van, Geert‐Jan Creemers, Sjoerd Rodenhuis, et al.. (1996). Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemotherapy and Pharmacology. 38(3). 254–260. 32 indexed citations
15.
Warmerdam, L.J.C. van, Olaf van Tellingen, R. A. A. Maes, & Jos H. Beijnen. (1995). Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius Journal of Analytical Chemistry. 351(8). 777–781. 63 indexed citations
16.
Warmerdam, L.J.C. van, Jaap Verweij, Jan H.M. Schellens, et al.. (1995). Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemotherapy and Pharmacology. 35(3). 237–245. 84 indexed citations
17.
Warmerdam, L.J.C. van, Sjoerd Rodenhuis, W.W. ten Bokkel Huinink, R. A. A. Maes, & Jos H. Beijnen. (1995). Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemotherapy and Pharmacology. 37(3). 266–270. 38 indexed citations
18.
Warmerdam, L.J.C. van, W.W. ten Bokkel Huinink, R. A. A. Maes, & Jos H. Beijnen. (1994). Limited-sampling models for anticancer agents. Journal of Cancer Research and Clinical Oncology. 120(7). 427–433. 61 indexed citations
19.
Warmerdam, L.J.C. van, et al.. (1994). Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemotherapy and Pharmacology. 35(2). 179–181. 20 indexed citations
20.
Burger, David M., L.J.C. van Warmerdam, Hilde Rosing, et al.. (1993). Development and Validation of Limited-Sampling Models for the Antiretroviral Agent Zidovudine. Clinical Drug Investigation. 6(4). 189–197. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert J. Cersosimo Breakdown of academic impact, for papers by Jill Kolesar Breakdown of academic impact, for papers by Von Hoff Breakdown of academic impact, for papers by Roberta Maltoni Breakdown of academic impact, for papers by F Larra Breakdown of academic impact, for papers by Virginia E. Kwitkowski Breakdown of academic impact, for papers by Justin D. Floyd Breakdown of academic impact, for papers by Els O. Witteveen Breakdown of academic impact, for papers by Pilar Zamora Breakdown of academic impact, for papers by Călin Cainap
Rankless by CCL
2026